Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Matthew Herper covers medical innovation — both its promise and its perils. Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron ...

The 10-second video shows the rapper playing with a football and an ending tag, “See you at the game,” with the Pfizer logo. Additional teasers will be posted Saturday and Sunday mornings ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. (AP Photo/Mark Lennihan, File) A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Pfizer’s stock has dropped in the double digits over three years. The company faces declines in sales of its coronavirus products and the loss of exclusivity of other major products. But over ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

Pfizer now expects 2024 earnings to wind up well above analyst expectations after starting the year with a forecast that disappointed Wall Street. The drugmaker also said Tuesday that sales growth ...